For people who pay out of pocket, Lilly recently introduced vials of its drug Zepbound that cost as little as 399 dollars a month. To compete, Novo Nordisk ramped up its rebating -- average Wegovy ...

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk's stock dropped by more than 4% following disappointing results from a Phase 2a trial of its obesity pill, Monlunabant. The experimental drug, acquired through Inversago Pharmaceuticals, ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month. Novo Nordisk's Wegovy Gets EU Backing to Treat ...